Oxeladin
As of the edition of 20 October 2026, Oxeladin is a small molecule: marketed, first approved in 1996 (FR).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Small molecule
- Brand name
- Paxeladine
- First approved
- 20 September 1996 (FR)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Ipsen
- Withdrawn from market
- 1 January 1994 (in some regions)
- Registered trials
- 2, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 4 | 1 | 0 | 1 | 0 |
| All trials | 2 |